The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer

Abstract

Background: This study sought to investigate the association between the ERCC1/2 single-nucleotide polymorphisms (SNPs) and the efficacy of radiotherapy and prognosis in patients with non-small cell lung cancer (NSCLC). Methods: We examined 6 SNPs in the ERCC1 and ERCC2 genes in 87 consecutive patients with NSCLC who were treated with definitive radiotherapy. The objective remission rates (ORR), overall survival (OS), and progressive-free survival (PFS) were assessed. A Cox regression analysis was conducted to analyze the independent factors related to death and recurrence. Result: Patients with the G allele had better OS than patients with the A allele, and there was a statistical difference between the two groups (30.9 vs. 16.2 months; P=0.003). Patients with the AA genotype had significantly worse OS than patients with the AG or GG genotypes (6.8 vs. 19.8 vs. 30.9 months, respectively; P=0.000). The median PFS of the G allele was 18.9 months, which was significantly better than that of the A allele (P=0.040). The median PFS of patients with the GG genotype, the AG genotype, and the AA genotype was 18.9, 11.3, and 5.1 months, respectively; the difference among the three groups was statistically significant (P=0.019). Patients with the G allele also had better PFS than those with the A allele (18.9 vs. 11.3 months, P=0.040). The multivariate cox proportional hazard analysis showed that the ERCC1 gene rs11615 was an independent survival indicator [HR: 1.623, 95% confidence interval (CI): 1.018-2.591, P=0.042] but not an independent recurrence indicator (HR: 1.497, 95% CI: 0.932-2.404, P=0.095). Conclusions: The ERCC1 rs11615 SNP may be a potential biomarker for predicting survival prognosis in Chinese NSCLC patients who have undergone definitive radiotherapy. Patients with the G allele had better OS than those with the A allele.

Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma

“…Within this frame, the identification of biomarkers that can predict radiation sensitivity and/ or clinical outcomes will enable NPC patients to benefit from a personalized therapy. Many studies in the last few decades have reported that SNPs in DNA repair genes could be correlated with radiotherapy response in a variety of cancers, including non-small cell lung cancer (NSCLC) (Jiang et al, 2021), rectal cancer (Qin et al, 2015), breast cancer (Lee et al, 2020), head and neck squamous cell carcinoma (HNSCC) (Jin et al, 2014) and NPC (Borchiellini et al, 2017).…”

“…Worldwide, the association between ERCC1 C118T SNP and chemoand/or radio-therapy outcome is well documented and discussed in different cancers. In this field, Jiang et al have shown that this SNP can play an important role in the prediction of radiotherapy sensitivity and prognosis of NSCLC (Jiang et al, 2021). Indeed, NSCLC patients carrying the C allele (CC or CT genotypes) had a significantly better survival compared to those bearing the T allele (TT genotype) (30.9 vs. 16.2 months; P=0.003).…”

Biological Mechanisms to Reduce Radioresistance and Increase the Efficacy of Radiotherapy: State of the Art

“…They demonstrated that mutations in the PIK3CA gene, coding for the catalytic subunit p110 of the phosphatidylinositol 3′-kinase (Pl3K), are related to cell radiosensitivity. On the other hand, a relationship between RT efficacy and genetic polymorphism in the DNA repair genes ERCC1/2 has been demonstrated in patients affected by NSCLC [ 57 , 58 ]. Gong et al [ 59 ] demonstrated the association between RT efficacy and rs 25487 polymorphism in the DNA repair gene XRCC1 in patients affected by esophageal cancer.…”